Skip to main content Help with accessibility Skip to main navigation

Aflibercept

Indication

Macular oedema secondary to central retinal vein occlusion (NICE TA305)

NICE TA305 - Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion 

Red

Brand:

Eylea®

Nice TA:

305

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Eye

Background

Aflibercept solution for injection is recommended as an option for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion only if the manufacturer provides aflibercept solution for injection with the discount agreed in the patient access scheme.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

Pending
Red
Red
Pending
Red
Red
Red
Red
What do the colours mean?

Last Updated: 01 - Mar - 2014